The Manufacturers Life Insurance Company Has $25.67 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

The Manufacturers Life Insurance Company decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 43.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 109,102 shares of the biopharmaceutical company's stock after selling 82,280 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Alnylam Pharmaceuticals worth $25,673,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $1,045,822,000. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $577,941,000. Capital Research Global Investors raised its position in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after purchasing an additional 315,182 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 2.0 %

ALNY traded up $5.31 during mid-day trading on Wednesday, hitting $275.12. The stock had a trading volume of 397,018 shares, compared to its average volume of 891,438. The stock's fifty day simple moving average is $249.46 and its 200-day simple moving average is $254.65. The firm has a market capitalization of $35.79 billion, a price-to-earnings ratio of -126.85 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 1-year low of $144.73 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on ALNY shares. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright restated a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Finally, Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Insider Activity

In related news, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,392 shares of company stock worth $1,875,627 in the last 90 days. Corporate insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.